Biometric monitoring devices for assessing end points in clinical trials: Developing an ecosystem

Nature Reviews Drug Discovery

Volumn 16, Issue 10, 2017, Pages 736-

  Arneric, Stephen P ^a   Cedarbaum, Jesse M ^b   Khozin, Sean ^c   Papapetropoulos, Spyros ^d   Hill, Derek L ^e   Ropacki, Michael ^f   Rhodes, Jane ^b   Dacks, Penny A ^h   Hudson, Lynn D ^b   Gordon, Mark Forrest ⁱ   Kern, Volker D ^a   Romero, Klaus ^a   Vradenburg, George ^j   Au, Rhoda ^k   Karlin, Daniel R ^l   Facheris, Maurizio F ⁿ   Fitzer Attas, Cheryl J ^o   Vitolo, Ottavio V ^m   Wang, Jian ^p   Miller, Bradley M ^p   Kaye, Jeffrey A ^g   more..

^a CRITICAL PATH INSTITUTE   (United States)

^b BIOGEN   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e IXICO PLC   (United Kingdom)

^f LOMA LINDA UNIVERSITY   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h American Epilepsy Association   (United States)

ⁱ Teva Pharmaceutical Industries   (United States)

^j USAgainst Alzheimer's   (United States)

^k BOSTON UNIVERSITY   (United States)

^l ABBVIE INC   (United States)

^m CHDI MANAGEMENT CHDI FOUNDATION   (United States)

ⁿ PFIZER INC   (United States)

^o Homology Medicines Inc   (United States)

^p ELI LILLY AND COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; BIOMETRIC MONITORING DEVICE; BIOMETRY; DECISION MAKING; DISEASE COURSE; HUMAN; INFORMATION PROCESSING; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; RELIABILITY; SAMPLE SIZE; STANDARDIZATION; VALIDATION STUDY; CLINICAL TRIAL (TOPIC); COMPUTER NETWORK; DEVICES; DISEASE EXACERBATION; DRUG DEVELOPMENT; DRUG MONITORING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHYSIOLOGIC MONITORING; PROCEDURES; REMOTE SENSING; TELEMETRY;

CLINICAL TRIALS AS TOPIC; COMPUTER COMMUNICATION NETWORKS; DISEASE PROGRESSION; DRUG DISCOVERY; DRUG MONITORING; HUMANS; MONITORING, PHYSIOLOGIC; PATIENT COMPLIANCE; PATIENT OUTCOME ASSESSMENT; REMOTE SENSING TECHNOLOGY; TELEMETRY;

EID: 85032508559     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2017.153     Document Type: Letter

References (10)

1. Kingwell, K. FDA eyes new diabetes end points. Nat. Rev. Drug Discov. 15, 666-667 (2016).
2. Delude, C. M. Deep phenotyping: The details of disease. Nature 527, S14-S15 (2015).
3. Espay, A. J. et al. Technology in Parkinson's disease: challenges and opportunities: technology in PD. Mov. Disord. (2016). doi:10. 1002/mds. 26642
4. Kaye, J. et al. Unobtrusive measurement of daily computer use to detect mild cognitive impairment. Alzheimers Dement. 10, 10-17 (2014).
5. Dodge, H. H., Mattek, N. C., Austin, D., Hayes, T. L. & Kaye, J. A. In-home walking speeds and variability trajectories associated with mild cognitive impairment. Neurology 78, 1946-1952 (2012).
6. Austin, D., Cross, R. M., Hayes, T. & Kaye, J. Regularity and predictability of human mobility in personal space. PLoS ONE 9, e90256 (2014).
7. Dodge, H. H., Zhu, J., Lee, C.-W., Chang, C.-C. H. & Ganguli, M. Cohort effects in age-associated cognitive trajectories. J. Gerontol. A. Biol. Sci. Med. Sci. 69, 687-694 (2014).
8. Hayes, T. L., Riley, T., Mattek, N., Pavel, M. & Kaye, J. A. Sleep habits in mild cognitive impairment. Alzheimer Dis. Assoc. Disord. 28, 145-150 (2014).
9. Dodge, H. H. et al. Use of high-frequency in-home monitoring data may reduce sample sizes needed in clinical trials. PLoS ONE 10, e0138095 (2015).
10. Walton, M. K. et al. . Clinical outcome assessments: conceptual foundation-report of the ISPOR Clinical outcomes assessment-emerging good practices for outcomes research task force. Value Health 18, 741-752 (2015).